fashion -WSS

fashion

author：knowledge 2025-09-28 00:49:42 - browse：14947

Yichuan Cao/Sipa USA via AP Images

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed.

The result, from a closely watched study called Evoke-01, will be seen as a disappointment by investors and oncologists alike.

Drugs like Trodelvy, known as antibody drug conjugates, are one of the hottest areas in oncology. The idea is that these medicines combine an antibody, which is triggered when it binds to a protein on a cancer cell, with a “payload” of chemotherapy that poisons the cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： More doctors should go into startup world

WSS

Excited delirium, Elijah McClain, and emergency physicians

Just how powerful is the placebo effect?

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Sanofi CEO defends move to abandon profit guidance, boost research

Medicare solvency divides Republicans at the presidential debate

UCSF medical school apologizes for unethical prisoner experiments

entertainment

fashion

knowledge

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Medicare will require more price transparency from hospitals

BioMarin wins approval for gene therapy to treat hemophilia A

Ukraine and a new approach to mental health in war

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Will General Catalyst be the first of many hospital takeovers?

23andMe had bad news about my health. I wish a person had delivered it

FDA panel to weigh approval of NurOwn, controversial ALS drug

Wildfire smoke exposes gaps in outdoor worker protections

Senators: Long

knowledge

FDA approves Recor Medical high blood pressure device

CommonSpirit Health keeps growing, even as it loses money

Biotech stock slump in 2023: awaiting the turnaround

Emergency workers more likely to restrain Black patients: study

MoonLake credibility takes another hit with mid

Readout LOUD podcast: possible new ALS drug, artificial wombs

knowledge

hotspot

entertainment

entertainment